Small Cell Lung Cancer Clinical Trial
Official title:
Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
Lung cancer is currently the leading cause of cancer death in both men and women in Europe, with an estimated 250000 new cases diagnosed in 2005. The continued poor outcome of patients indicates that the current recommended regimens are falling short. In addition, many of the commonly used chemotherapy agents are associated with severe nonhematologic toxicities that are often cumulative and nonreversible and impair quality of life in this essentially palliative setting. Therefore, agents with novel mechanisms of action and superior safety profiles need to be investigated. More than 50% of lung cancer shows carcinoembryonic antigen (CEA) expression and anti-CEA radioimmunotherapy (RAIT) could be used. The investigators group showed that pretargeted RAIT (PRAIT) using bispecific antibody (bsMAb) can deliver a higher radiation dose to a tumor than a directly radiolabeled anti-CEA antibody, and shows improved anti-tumor efficacy. This clinical trial is designed to assess PRAIT using an entirely new recombinant anti-CEA bsMAb and a 177Lu-labeled peptide for the treatment of CEA-expressing small cell lung cancers (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
The purpose of this open-label prospective optimization and phase I/II clinical trial is to
examine the safety, optimal dose, targeting, dosimetry and efficacy of PRAIT using the
humanized anti-CEA x anti-HSG bsMAb TF2 and the 177Lu-IMP-288 peptide pretargeted in
patients with CEA-positive SCLC or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
This study has 2 parts: Study plan I (Optimization study) and Study plan II (Escalating
activity phase I/II study).
The Study plan I is designed to optimize the pretargeting procedure using blood
pharmacokinetics (Pk) and dosimetry in 9 patients receiving escalating doses of TF2 followed
2 to 4 days later by 1.1 GBq/m2 of 177Lu-IMP-288.
The study plan II is designed to determined MTD of 177Lu-IMP-288 using dosimetry and
toxicity data in a phase I/II study performed in patients receiving optimal dose of TF2
bsMAb (determined in study plan I) followed 2 to 4 days by escalating activity of
177Lu-IMP-288.
A pre-therapy imaging study (using TF2 followed 2 to 4 days later by 185 MBq of
111In-IMP-288) is performed in the two study plans to qualify a patient for treatment with
the subsequent therapy dose.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03651219 -
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03958045 -
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
|
Phase 2 | |
| Completed |
NCT04381910 -
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04885998 -
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
|
Phase 1 | |
| Active, not recruiting |
NCT03703297 -
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
|
Phase 3 | |
| Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT04422210 -
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
|
Phase 1 | |
| Not yet recruiting |
NCT02875457 -
Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin
|
Phase 3 | |
| Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
| Completed |
NCT02551432 -
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT02262897 -
The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01943578 -
Value of Physical Capacity Tests in Lung Cancer
|
N/A | |
| Terminated |
NCT00969306 -
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients
|
Phase 1 | |
| Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01497873 -
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00958022 -
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT00930891 -
Bevacizumab in Extensive Small Cell Lung Cancer
|
Phase 2/Phase 3 |